inVentiv closes i3 deal
13 June 2011 | Jonathan Hare Scrip Clinical Research
Can India's Syngene best WuXi? Interview: Dr Reddy's CEO on move from curing diseases to managing health BioNotebook: Blend raises VC cash; Actavis gets quick Namenda appeal; and three new deals Fudged ECG reports: GVK blunder or overblown storm?
Other Features & Analysis
Expert view: Navigating the changing landscape of transfer pricing Conducting drug clinical trials in Russia: today and what lies ahead Cracking the consumer health talent code: driving home pharma's advantage Pharma challenge: don't let change drain your value